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Abstract
FADD (Fas Associated protein with Death Domain) is a key adaptor molecule transmitting the
death signal mediated by death receptors. In addition, this multiple functional protein is implicated
in survival/proliferation and cell cycle progression. FADD functions are regulated via cellular
sublocalization, protein phosphorylation, and inhibitory molecules. In the present review, we focus
on the role of the FADD adaptor in cancer. Increasing evidence shows that defects in FADD
protein expression are associated with tumor progression both in mice and humans. Better
knowledge of the mechanisms leading to regulation of FADD functions will improve understanding
of tumor growth and the immune escape mechanisms, and could open a new field for therapeutic
interventions.
The FADD molecule
The FADD gene is located on chromosome 11q13.3 in
humans and 7 in mice [1]. Mutations in the FADD gene
containing locus are frequently observed in human malig-
nancies [2]. For instance, the 11q13 region contains the
fibroblast growth factor 3 and 4 genes which are coampli-
fied in melanoma. It also includes the multiple endocrine
neoplasia I gene whose mutation leads to tumor develop-
ment of several endocrine glands including thyroid. More-
over, two genes implicated in leukemia are found in this
locus: NUMA1 which is translocated in acute promyelo-
cytic leukemia, and BCL1 which is located very close to
the FADD gene and is mutated in B-cell leukemia/lym-
phoma. Although FADD has a central role in multiple
receptor-induced cell death as discussed hereafter, no
mutation of the FADD gene itself has been reported so far.
Human and mouse FADD genes have the same quite sim-
ple organization consisting of two exons (286 bp and 341
bp in humans; 332 bp and 286 bp in mice) separated by
a unique intron of approximately 2 kb. Interestingly, no
cap site was reported on the human FADD mRNA [1], sug-
gesting a particular regulation of FADD mRNA transla-
tion, although this topic has not been further investigated.
Human and mouse FADD proteins are very similar (Fig-
ure 1). They consist of 208 and 205 amino acids (AA)
respectively, and share 80% similarity and 68% identity
[3]. FADD mRNA and protein are almost ubiquitously
expressed in fetal and adult tissues, both in humans and
mice [4]. Two domains are particularly well conserved
between species: the death domain (DD) at the COOH-
terminus of the protein, and the death effector domain
(DED) at the NH2-terminus of the protein [5,6]. Both
domains play a crucial role in transducing the apoptotic
signal mediated by death receptors. Furthermore, a single
serine (Ser) phosphorylation site essential for determin-
ing cell cycle progression is conserved in both species
(human Ser 194 [7] and mouse Ser 191 [8]).
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Since the first role ascribed to FADD was to transmit apop-
totic signals through its interaction with death receptors
expressed at the cell membrane, it was assumed that
FADD protein was exclusively localized in the cytoplasm
of the cell. However, a nuclear localization sequence
(NLS) and a nuclear export sequence (NES) were recently
identified in the human FADD protein (Figure 1), and
account for FADD protein expression in the nucleus and
the cytoplasm of the cell, respectively [9]. The vast major-
ity of the reports on FADD focused on the cytoplasmic
FADD protein because of its pro-apoptotic function. In
contrast, the role of the nuclear FADD is much more mys-
terious. It was recently reported that FADD expression in
the nucleus protects cells from apoptosis, but the mecha-
nism implicated in this survival function has not been
investigated [9]. On the other hand, it has been shown
that FADD could interact within the nucleus of adherent
cells with the methyl-CpG binding domain protein 4
(MBD4) [10]. MBD4 is a GT mismatch repairing protein.
Association between MBD4 and FADD within the nucleus
could couple MBD4-mediated genome surveillance with
FADD-mediated cell death. Thus, nuclear FADD could
perhaps have a pro-apoptotic function, at least in
response to DNA-damaging agents.
Functions of the FADD protein
An essential molecule for embryonic development
The essential role of the FADD molecule was highlighted
by generating FADD mutant null mice [11,12]. Indeed,
FADD knockout mice were not viable. FADD null
embryos died in utero at day 12.5 of development, due to
underdevelopment, abdominal hemorrhage, and cardiac
failure. Moreover, FADD loss of function did not result in
a lymphoproliferative disorder as observed in viable Fas
mutant mice [13,14]. These results indicated that in addi-
tion to its well known role in cell death, FADD was also
implicated in survival/proliferation of some cell types.
A main death transducer for DD-containing receptors
FADD is the main signal transducing intermediate adap-
tor molecule of several death receptors including Fas,
TNF-R1 (tumor necrosis factor receptor 1), DR3 (death
receptor 3), TRAIL-R1 (TNF-related apoptosis-inducing
ligand, DR4), and TRAIL-R2 (DR5) [4,11,12,15]. All these
receptors possess, in their intra-cytoplasmic tail, a DD
homologous to the DD of FADD allowing FADD recruit-
ment to the activated receptor. FADD can be recruited
either directly to Fas and TRAIL-Rs (Figure 2A) or indi-
rectly to TNF-R1 (Figure 2B). In the latter case, FADD is
recruited via another DD-containing adaptor molecule
(TRADD, TNF receptor-associated protein with DD).
Next, FADD recruits DED-containing initiator pro-caspase
8 or 10 through DED/DED interactions [16-18], thus
forming the death-inducing signaling complex (DISC)
[19]. Autoprocessing of initiator pro-caspase leads to acti-
vation of effective caspases which cleave intracellular sub-
strates, causing the apoptotic death of the cell [20,21].
Control of FADD recruitment to the DISC can occur fol-
lowing several mechanisms depending on the cell type
and the death receptor [22]. The best characterized death
receptor signaling inhibitors are DED-containing viral
and cellular FLICE-inhibitory proteins (v-FLIPs and c-
FLIPs, respectively) [23,24]. Inhibition of Fas-, TNF-R1-,
and TRAIL-Rs-induced apoptosis by endogenous FLIPs
results from binding of the c-FLIPs to the DED of FADD,
Human and mouse FADD protein Figure 1
Human and mouse FADD protein. Amino acids (AA) corresponding to the human FADD protein are marked in black, 
whereas AA corresponding to the mouse FADD protein are marked in grey. The death domain (DD) and death effector 
domain (DED) are essential for interaction with death receptors and transmission of the apoptotic signal. Human nuclear 
export sequence (NES in red) and nuclear localization sequence (NLS in blue) determine localization of the protein in the cyto-
plasm and the nucleus, which are associated with cell death and survival functions of the FADD protein, respectively. Human 
Ser 194 and mouse Ser 191 phosphorylation site (in purple) have a crucial role in survival/proliferation and cell cycle 
progression.Medical Immunology 2005, 4:1 http://www.medimmunol.com/content/4/1/1
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Apoptosis mediated by death receptors requires the FADD adaptor molecule Figure 2
Apoptosis mediated by death receptors requires the FADD adaptor molecule. (A) Engagement of a Fas ligand 
trimer on a trimer of Fas leads to FADD adaptor molecule recruitment through homotypic DD interactions. FADD next binds 
initiator pro-caspase through DED interactions. This Fas/FADD/pro-caspase complex forms the Fas death-inducing signaling 
complex (DISC) since initiator pro-caspase activates a caspase cascade resulting in apoptotic death of the cell. Alternatively, c-
FLIPs can promote cell survival by interacting with FADD through their respective DED, thus hindering recruitment and activa-
tion of initiator pro-caspase. (B) Signaling mediated by TNF-R1 implicates formation of two sequential complexes [61]. The 
complex I (in blue) contains the TNF-R1, the adaptor TRADD, the receptor interacting kinase (RIP), and the TNF-receptor 
associated factor 2 (TRAF2). It assemblies rapidly following TNF-α stimulation and activates the NF-kB pathway which in turn 
induces expression of survival genes, including c-FLIP. Later on, complex I dissociates from the TNF-R1 and is internalized. 
FADD can then bind the liberated DD of TRADD and recruits initiator pro-caspase, forming complex II (in red) which is cyto-
plasmic. Activation of initiator pro-caspase 8/10 in complex II results in apoptosis of the cell. Red box: DD; hatched red box: 
DED.Medical Immunology 2005, 4:1 http://www.medimmunol.com/content/4/1/1
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thus hindering pro-caspase 8 activation (Figure 2A). Sim-
ilarly, v-FLIPs inhibit apoptosis mediated by death recep-
tors either by binding to FADD and blocking pro-caspase
8 processing, or by binding to pro-caspase 8 and inhibit-
ing FADD interaction. Therefore, equilibrium between
FADD and the expression of its inhibitors determines the
outcome of the death receptor-stimulated cell, i.e. apopto-
sis or survival.
All the main death receptors described up to now require
FADD adaptor for transmitting their apoptotic signal.
Consequently, FADD is a central protein that controls
multiple essential cellular processes including cellular
homeostasis and elimination of pathological cells, partic-
ularly during the course of an immune response.
Death receptor independent FADD induced apoptosis
Formation of cytoplasmic death effector filaments (DEF)
by oligomerization of DED-containing proteins, includ-
ing FADD, is responsible for death receptor independent
cellular apoptosis [25]. Indeed, FADD over-expression by
itself is known to induce cell death through DEF forma-
tion that recruits and activates pro-caspase 8. However,
the existence of DEF has not been established in vivo, and
increasing evidences suggest that DEF could be artefactual
structures resulting from protein over-expression. As a
consequence, the ability of endogenous FADD to aggre-
gate and form DEF in normal situation should be
reconsidered.
Functions in proliferation and cell cycle progression
Beside being a main death adaptor molecule, FADD is
also required for T cell proliferation. The first evidence of
this property of FADD came from observations made in
chimeric FADD knockout mice. Five-week-old chimeric
FADD-/- mice presented a lack of thymocytes compared to
wild type animals, with few or no CD4+ CD8+ double pos-
itive thymocytes remaining [12]. Moreover, several groups
have demonstrated that FADD deficiency in peripheral T
lymphocytes resulted in an inhibition of mitogen-
induced T cell proliferation [12,26-30]. The mechanism
leading to FADD-dependent T cell proliferation did not
involve the early events associated with cell proliferation
since expression level and functionality of the IL-2 recep-
tor, level of IL-2 secretion, mobilization of intracellular
calcium, and activation of NF-kB, p38-MAPK, and p44/
42-MAPK appeared normal in FADD-/- T lymphocytes
[12,29,30]. Recent data showed that FADD-/-  T lym-
phocytes entered the cell cycle upon mitogenic stimula-
tion, but died during progression through the cell cycle
[30]. Therefore, lack of proliferation of FADD-deficient T
cells results from defective survival associated with pro-
gression through the cell cycle rather than defective activa-
tion. Up to now, the molecular pathway implicated in
FADD-mediated survival of lymphocytes has not been
described.
In addition to impairing survival during cell division,
FADD deficiency also leads to a dysregulation of the cell
cycle machinery [31]. The pattern of expression of mole-
cules implicated in both G1/S and G2/M transitions was
aberrant in FADD-/- lymphocytes, resulting in spontane-
ous entry and progression through the cell cycle of 10% of
freshly isolated FADD-/- T cells (as compared to less than
2% of wild type T cells) [31].
The mechanisms responsible for FADD regulation of cell
cycle progression are not fully understood. However, the
phosphorylation of the 194 human and 191 mouse Ser of
the protein (Figure 1) has recently drawn attention.
Indeed, human FADD was phosphorylated at Ser 194, by
a still unidentified 70 kDa protein kinase, in cells arrested
in G2/M, whereas it was unphosphorylated in G1/S [7].
Generation of FADD Ser 191 mutant mice confirmed that
FADD phosphorylation is involved in proliferation in vivo
[8]. Replacement of Ser 191 by an aspartic acid resulting
in constitutive phosphorylation of the FADD protein led
to abnormal development of FADD mutant mice that
shared the same phenotype as FADD deficient mice [8],
including few CD4+ CD8+ thymocytes and defective pro-
gression through the cell cycle [12,31].
Tumor cells are constantly cycling cells. Although it does
not seem to directly affect the cell cycle progression,
FADD phosphorylation at Ser 194 sensitizes these cells to
reagents that induce G2/M arrest such as the Taxol anti-
cancer drug [32]. In human prostate cancer cell lines,
treatment with Taxol resulted in Ser 194 FADD phospho-
rylation and G2/M arrest [33]. Moreover, etoposide or cis-
platin chemotherapeutic drug-induced apoptosis of these
cells was enhanced by pretreatment with Taxol, a process
that was inhibited by cellular over-expression of an
unphosphorylable FADD mutant [33]. Therefore, tumor
cells that express a Ser 194 FADD mutant that cannot be
phosphorylated or are unable to phosphorylate FADD at
this Ser position are expected to resist apoptosis induced
by anticancer drugs that induce G2/M arrest, and to be
insensitive to the synergistic effect of chemotherapy.
Obviously, a lack of FADD expression will have the same
consequences.
Role in tumor development
FADD as a tumor suppressor
The role of the FADD adaptor in cancer was initially dem-
onstrated by generating RAG-1 deficient transgenic mice
that target expression of a FADD dominant negative
mutant in lymphocytes. With age these mice developed
thymic lymphoblastic lymphoma, whereas FADD+/+ RAG-
1-/- mice did not [34]. Moreover, thymic lymphoblasticMedical Immunology 2005, 4:1 http://www.medimmunol.com/content/4/1/1
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lymphomas were never observed in FADD-/- RAG-1+/+ or
FADD-/-  RAG-1+/-  mice, demonstrating that absence of
FADD expression was necessary but not sufficient to
induce tumor development in this model [34]. These
results were the first demonstration that FADD adaptor
can act as a tumor suppressor in vivo.
Using a mouse model of thyroid adenoma/adenocarci-
noma, we showed spontaneous disappearance of FADD
protein expression during the course of tumor develop-
ment [35]. The so called gsp transgenic mice expressed an
oncogene specifically in thyroid follicular cells (TFC), and
developed thyroid hyperplasia that eventually trans-
formed into hyperfunctioning adenomas or adenocarci-
nomas around the age of 8 months [36]. The fact that gsp
mice developed hyperfunctioning adenomas or adenocar-
cinomas belatedly suggested that oncogene expression
conferred a predisposition but that an additional event
was necessary for thyroid tumor development. We found
that FADD protein was highly expressed in all non-patho-
logical and in almost all hyperplastic thyroid glands from
gsp mice. In contrast, thyroid adenoma/adenocarcinoma
expressed low or no FADD protein [35]. These results
raised the possibility that loss of FADD protein expression
could be an additional event contributing to tumorigene-
sis, and suggested that FADD plays a role as a tumor
suppressor.
We recently showed that absence of FADD protein expres-
sion in cancer cells is also a relevant phenomenon in
human malignancies [37]. We looked for FADD protein
expression in human acute myeloid leukemia (AML) cells.
Leukemic cells of most AML patients are resistant to Fas-
mediated cell death despite expressing the Fas receptor
[38] and/or the FasL molecule [39]. Moreover, chemo-
therapeutic drugs used for AML treatment can kill target
cells via several mechanisms, including death receptor-
induced apoptosis [40-43]. We performed a retrospective
study of 70 consecutive patients with de novo AML treated
homogeneously, and found that leukemic cells of 2/3 of
patients at diagnosis expressed low or no FADD protein
[37]. Moreover, in this cohort of patients, we showed that
absent/low FADD protein expression in AML cells at diag-
nosis was a new independent prognostic factor for poor
response to chemotherapy (in terms of complete remis-
sion rate, event free and overall survivals) [37]. Impor-
tantly, absent/low FADD protein expression in AML cells
at diagnosis was a prognostic factor even for patients clas-
sified as standard- or good-risk AML cases by cytogenetic
and molecular criteria [37]. As a consequence, this new
prognostic factor is of clinical importance since it will
allow early identification of patients with chemoresistant
AML who could benefit from more intensive post-remis-
sion therapy.
Absence of FADD confers numerous advantages on cancer 
cells
The fact that absence of FADD expression was found in
different types of tumor cells both in mice and humans
strongly suggested that absence of FADD contributed to
tumor development. Indeed, lack of FADD protein can
confer numerous advantages on pathological cells, which
predominantly result in tumor survival/growth gain (Fig-
ure 3).
Immune escape and resistance to chemotherapy
Fas, TRAIL-Rs, TNF-R1, DR3, and potentially other recep-
tors use FADD adaptor for transmitting the death signal.
Thus, absence of FADD expression in tumor cells must
confer multiple resistance of these cells to death receptor
cytotoxicity. In agreement with this assumption, we
observed that FADD-/- TFC as well as FADD-/- AML cells
were resistant to Fas- and TNF-α-mediated apoptosis [35],
and unpublished data). Since cytotoxic tumor infiltrating
lymphocytes (TIL) use, among other mechanisms, death
receptor-mediated cell death to kill pathological cells,
tumor cells lacking FADD molecule expression may par-
tially avoid immune attack (Figure 3A). On the other
hand, some anticancer drugs exert their cytotoxic effect by
inducing death receptor and/or death ligand expression
on tumor cells, thereby inducing suicidal/fratricidal apop-
tosis of the cells. For instance, anthracyclines and etopo-
side, two chemotherapeutic drugs used for AML
treatment, enhance Fas- and TRAIL-R2-mediated cell
death in vitro, a process requiring FADD molecule expres-
sion [40-42,44,45]. As a consequence, absence of FADD
expression in AML cells of our patients may contribute to
chemoresistance of leukemic cells (Figure 3A).
Tumor counter-attack
As described above, absence of FADD allows co-expres-
sion of death receptors and ligands without inducing
autocrine or paracrine apoptosis of tumor cells. For
instance, although the Fas receptor was expressed at all
stages of thyroid tumor development in gsp mice, FasL
expression was gained with a high expression in adenom-
atous/adenocarcinomatous glands [35]. Using the same
method, we found that leukemic cells of most AML
patients expressed FasL [39] and secreted TNF-α despite
expressing Fas and TNF-R1 [37], and unpublished data).
Moreover, co-expression of Fas and FasL molecules that
did not cause cell death was also observed in lymphoma
[46], melanoma [47], astrocytoma [48], cancers of the
colon [49], liver [50], lung [51], human thyroid [52]. The
role of death ligand expression in tumor cells is still a con-
troversial issue [53-55], but it is now well accepted that it
allows at least some cancer cells to kill TIL that express
death receptors, a process called the "tumor counter-
attack" (Figure 3B).Medical Immunology 2005, 4:1 http://www.medimmunol.com/content/4/1/1
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Lack of FADD expression confers survival/growth advantages on tumor cells Figure 3
Lack of FADD expression confers survival/growth advantages on tumor cells. Absence of FADD protein confers 
multiple death receptor-mediated apoptosis resistance and allows tumor cells to co-express death receptors and ligands with-
out committing cell death. (A) Lack of FADD contributes to immune escape and resistance to chemotherapy. FADD deficient 
tumor cells resist death receptor-mediated apoptosis induced by TIL and chemotherapeutic drugs. Anthracyclines increase Fas 
and FasL expression on tumor cells. Etoposide induces Fas receptor trimerization, leading to Fas-mediated cell death independ-
ently of FasL expression. Both drugs enhance TRAIL-R2-mediated apoptosis. (B) Lack of FADD contributes to tumor counter-
attack. Lack of FADD expression allows many types of tumor cells to express innocuously functional FasL that can kill TIL. 
Secretion of TNF-α by AML cells can have cytotoxic effects on TIL. (C) Lack of FADD contributes to tumor growth. In the 
absence of FADD, Fas signaling leads to a proliferative signal instead of an apoptotic one. Concomitant death receptor and lig-
and expression, in the absence of FADD, allows autocrine (in red) and paracrine (in orange) proliferation of tumor cells. Acti-
vated TIL can contribute to paracrine (in purple) proliferation of FADD-deficient tumor cells.Medical Immunology 2005, 4:1 http://www.medimmunol.com/content/4/1/1
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Proliferative advantage
Since the tumor counter-attack hypothesis cannot apply
to all types of cancer cells, one could wonder whether
other benefits of death ligand expression by tumor cells
exists. Previous reports demonstrated that Fas signaling
could lead to proliferation instead of apoptosis, depend-
ing on the cell type and the environmental conditions
[56-58]. For instance, agonistic anti-Fas antibody-induced
proliferation of hematological and non-hematological
tumors has been described [59]. Moreover, we have
shown that stimulation of FADD lacking thyrocytes by an
agonistic anti-Fas antibody resulted in accelerated growth
of TFC, via a particular Daxx adaptor-mediated pathway
[35]. Therefore, Fas signaling, particularly in the absence
of FADD, can confer proliferative advantage on tumor
cells (Figure 3C). Thus, FasL expression on Fas+ FADD-
adenomatous/adenocarcinomatous thyroid from gsp
mice, as well as on human AML cells, may allow both
autocrine and paracrine proliferation of these cells [35,37]
(Figure 3C). Furthermore, we can formulate the same
hypothesis for TNF-α secretion by TNF-R1 expressing
leukemic cells (Figure 3C). If our hypotheses are correct,
then activated TIL that express death ligands could
contribute to FADD-deficient tumor proliferation (Figure
3C).
Restoring FADD protein expression- a new therapeutic 
issue
Absence of FADD expression could confer multiple
growth advantages on cancer cells (Figure 3), and is
expected to contribute to disease progression. As a conse-
quence, finding how to restore FADD protein expression
in FADD-negative tumor cells represents a research field
with potentially direct clinical applications. In fact, it is
possible that some of the current cancer treatments act, at
least partially, through this mechanism. For instance, car-
boplatin is a cytotoxic drug potentially effective at reestab-
lishing functional FADD protein expression. Indeed, the
human tongue carcinoma cell lines SCC-9 and SCC-25
express very low levels of FADD protein. Moreover, treat-
ment with carboplatin enhances FADD protein expres-
sion, thus rendering cancer cells sensitive to Fas-mediated
apoptosis [60]. The combination of carboplatin with
chemotherapeutic drugs that induce death receptor-medi-
ated cell death may result in improved treatment.
Molecules implicated in FADD regulation of expression
also represent new therapeutic targets. However, very little
is known about the mechanisms leading to absent/low
FADD protein expression in tumor cells. In SCC-9 and
SCC-25 carcinoma cell lines, carboplatin upregulated
FADD protein expression by increasing FADD mRNA
[60]. However, FADD mRNA was normally expressed in
mouse thyroid adenoma/adenocarcinoma and in human
AML cells, and lack of FADD mRNA could not account for
poor FADD protein expression in these cancer cells
[35,37]. These results suggest that several mechanisms
could be implicated in loss of FADD protein, depending
on the type of cell and the environmental pressure.
Besides, docking FADD protein away from the death
receptor, in the nucleus for example, would have the same
consequences. Understanding such mechanisms is the
first necessary step towards development of new antican-
cer drugs targeting molecules that regulate FADD protein
expression.
Conclusion
FADD is mainly known as a key adaptor molecule for
numerous death receptors. However, increasing evidences
have shown that FADD is a much more complex molecule
implicated in apoptosis, survival, cell cycle progression,
and proliferation of the cells. Therefore, FADD plays a
central role in the frightening control of cell death and
life. As a consequence, a defect in the FADD molecule can
contribute to the development of diseases, and particu-
larly cancer. Absence of FADD protein expression is a
marker of tumor development in the mouse, and a prog-
nostic factor for poor response to chemotherapy in
humans. Since FADD deficiency could contribute to sev-
eral malignancies, in view of its almost ubiquitous pattern
of expression, study of the role of FADD in tumor devel-
opment, growth, and resistance to treatment, and under-
standing how the expression of this puzzling molecule is
regulated, are targets that merit further investigation.
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